{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:48:36Z","timestamp":1780498116331,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ad.2015.04.008","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T20:39:12Z","timestamp":1433536752000},"page":"550-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biosimilares en dermatolog\u00eda. Situaci\u00f3n actual (parte ii)"],"prefix":"10.1016","volume":"106","author":[{"given":"L.","family":"Puig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferr\u00e1ndiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Marr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"P\u00e9rez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rodriguez-Cerdeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"S\u00e1nchez-Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2015.04.008_bib0095","unstructured":"Inflectra Assessment report [consultado 25 Ene 2015]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002778\/WC500151490.pdf"},{"issue":"Suppl 3","key":"10.1016\/j.ad.2015.04.008_bib0100","article-title":"Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation","volume":"55","author":"Scott","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ad.2015.04.008_bib0105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2014.02.007","article-title":"Biosimilars: In support of extrapolation of indications","volume":"8","author":"Ebbers","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2015.04.008_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.ad.2015.04.008_bib0115","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.autrev.2014.02.004","article-title":"SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ad.2015.04.008_bib0120","first-page":"60","article-title":"Sociedade Portuguesa de Reumatologia. The Portuguese Society of Rheumatology position paper on the use of biosimilars","volume":"39","author":"Fonseca","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.ad.2015.04.008_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ad.2013.08.003","article-title":"Biosimilars and reference biologics: Decisions on biosimilar interchangeability require the involvement of dermatologists","volume":"105","author":"Puig","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.04.008_bib0130","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: The science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ad.2015.04.008_bib0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/mabs.3.3.15599","article-title":"Biosimilars 2.0: Guiding principles for a global patients first standard","volume":"3","author":"Miletich","year":"2011","journal-title":"MAbs"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2015.04.008_bib0140","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10198-014-0589-1","article-title":"Statistical and regulatory considerations in assessments of interchangeability of biological drug products","volume":"15","author":"Tothfalusi","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.ad.2015.04.008_bib0145","unstructured":"Biologics Price Competition and Innovation Act. Federal register. 2010; H.R. 3590-686-702. [consultado 8 May 2015]. Disponible en: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/UCM216146.pdf"},{"key":"10.1016\/j.ad.2015.04.008_bib0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/sim.5569","article-title":"On the interchangeability of biologic drug products","volume":"32","author":"Endrenyi","year":"2013","journal-title":"Statist Med"},{"key":"10.1016\/j.ad.2015.04.008_bib0155","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Documento de posicionamiento de la SER sobre f\u00e1rmacos biosimilares [consultado 25 Ene 2015]. Disponible en: http:\/\/www.ser.es\/actualidad\/noticias\/documento-de-posicionamiento-de-la-ser-sobre-farmacos-biosimilares\/1842"},{"key":"10.1016\/j.ad.2015.04.008_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4321\/S1130-01082013000100006","article-title":"Posici\u00f3n conjunta de la Sociedad Espa\u00f1ola de Patolog\u00eda Digestiva y de la Sociedad Espa\u00f1ola de Farmacolog\u00eda sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal","volume":"105","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.ad.2015.04.008_bib0165","unstructured":"Confederaci\u00f3n de Asociaciones de Enfermos de Crohn y Colitis Ulcerosa de Espa\u00f1a. Contra la intercambiabilidad de f\u00e1rmacos biosimilares. [consultado 25 Ene 2015]. Disponible en: http:\/\/accuesp.com\/news\/es\/2013\/05\/30\/0001\/contra-la-intercambiabilidad-de-farmacos-biosimilares"},{"key":"10.1016\/j.ad.2015.04.008_bib0170","article-title":"Biosimilars in psoriasis 2015: What is next?","author":"Puig","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2015.04.008_bib0175","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4161\/mabs.22276","article-title":"Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products","volume":"4","author":"Tan","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.ad.2015.04.008_bib0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-014-3080-5","article-title":"Etanercept biosimilars","volume":"35","author":"Azevedo","year":"2015","journal-title":"Rheumatol Int"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015002069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015002069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:03:38Z","timestamp":1757552618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731015002069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0001731015002069"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2015.04.008","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilares en dermatolog\u00eda. Situaci\u00f3n actual (parte ii)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2015.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}